Imprimis Pharmaceuticals Company Profile (NASDAQ:IMMY)

About Imprimis Pharmaceuticals (NASDAQ:IMMY)

Imprimis Pharmaceuticals logoImprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:IMMY
  • CUSIP: N/A
  • Web: www.imprimisrx.com
Capitalization:
  • Market Cap: $33.71 million
  • Outstanding Shares: 20,065,000
Average Prices:
  • 50 Day Moving Avg: $1.99
  • 200 Day Moving Avg: $3.03
  • 52 Week Range: $1.47 - $4.69
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $23.61 million
  • Price / Sales: 1.44
  • Book Value: $0.38 per share
  • Price / Book: 4.47
Profitability:
  • EBIDTA: ($13,240,000.00)
  • Net Margins: -57.07%
  • Return on Equity: -242.66%
  • Return on Assets: -52.73%
Debt:
  • Debt-to-Equity Ratio: 1.68%
  • Current Ratio: 1.88%
  • Quick Ratio: 1.55%
Misc:
  • Average Volume: 178,631 shs.
  • Beta: -0.16
  • Short Ratio: 4.05
 

Frequently Asked Questions for Imprimis Pharmaceuticals (NASDAQ:IMMY)

What is Imprimis Pharmaceuticals' stock symbol?

Imprimis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IMMY."

How were Imprimis Pharmaceuticals' earnings last quarter?

Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) issued its quarterly earnings data on Thursday, August, 10th. The company reported $0.06 EPS for the quarter, topping the Zacks' consensus estimate of ($0.23) by $0.29. The firm earned $6.86 million during the quarter. Imprimis Pharmaceuticals had a negative return on equity of 242.66% and a negative net margin of 57.07%. View Imprimis Pharmaceuticals' Earnings History.

When will Imprimis Pharmaceuticals make its next earnings announcement?

Imprimis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for Imprimis Pharmaceuticals.

Where is Imprimis Pharmaceuticals' stock going? Where will Imprimis Pharmaceuticals' stock price be in 2017?

2 analysts have issued 12-month target prices for Imprimis Pharmaceuticals' shares. Their predictions range from $5.00 to $5.00. On average, they anticipate Imprimis Pharmaceuticals' share price to reach $5.00 in the next year. View Analyst Ratings for Imprimis Pharmaceuticals.

Who are some of Imprimis Pharmaceuticals' key competitors?

Who are Imprimis Pharmaceuticals' key executives?

Imprimis Pharmaceuticals' management team includes the folowing people:

  • Robert J. Kammer D.D.S, Chairman of the Board
  • Mark L. Baum J.D., Chief Executive Officer, Director
  • Andrew R. Boll CFA, Chief Financial Officer, Secretary
  • John P. Saharek, Chief Commercial Officer
  • Stephen G. Austin CPA, Independent Director
  • Richard L. Lindstrom M.D., Independent Director
  • Anthony J. Principi J.D., Independent Director

Who owns Imprimis Pharmaceuticals stock?

Imprimis Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Marathon Asset Management LP (3.95%), Vanguard Group Inc. (2.25%), Granite Investment Partners LLC (1.41%), Berson & Corrado Investment Advisors LLC (0.56%), Bard Associates Inc. (0.30%) and Bank of New York Mellon Corp (0.18%). Company insiders that own Imprimis Pharmaceuticals stock include Andrew R Boll, Mark L Baum, Opaleye Management Inc, Richard L Md Lindstrom and Robert J Kammer. View Institutional Ownership Trends for Imprimis Pharmaceuticals.

Who sold Imprimis Pharmaceuticals stock? Who is selling Imprimis Pharmaceuticals stock?

Imprimis Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC and Berson & Corrado Investment Advisors LLC. View Insider Buying and Selling for Imprimis Pharmaceuticals.

Who bought Imprimis Pharmaceuticals stock? Who is buying Imprimis Pharmaceuticals stock?

Imprimis Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and Bank of New York Mellon Corp. Company insiders that have bought Imprimis Pharmaceuticals stock in the last two years include Andrew R Boll, Mark L Baum, Opaleye Management Inc and Richard L Md Lindstrom. View Insider Buying and Selling for Imprimis Pharmaceuticals.

How do I buy Imprimis Pharmaceuticals stock?

Shares of Imprimis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Imprimis Pharmaceuticals' stock price today?

One share of Imprimis Pharmaceuticals stock can currently be purchased for approximately $1.70.


MarketBeat Community Rating for Imprimis Pharmaceuticals (NASDAQ IMMY)
Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  53 (Vote Outperform)
Underperform Votes:  58 (Vote Underperform)
Total Votes:  111
MarketBeat's community ratings are surveys of what our community members think about Imprimis Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Imprimis Pharmaceuticals (NASDAQ:IMMY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.00 (194.12% upside)

Analysts' Ratings History for Imprimis Pharmaceuticals (NASDAQ:IMMY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/22/2017Rodman & RenshawReiterated RatingBuy$5.00HighView Rating Details
11/28/2016HC WainwrightInitiated CoverageBuy$5.00N/AView Rating Details
(Data available from 9/23/2015 forward)

Earnings

Earnings History for Imprimis Pharmaceuticals (NASDAQ:IMMY)
Earnings by Quarter for Imprimis Pharmaceuticals (NASDAQ:IMMY)
Earnings History by Quarter for Imprimis Pharmaceuticals (NASDAQ IMMY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017N/AView Earnings Details
8/10/2017Q2 2017($0.23)$0.06$6.86 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.19)($0.26)$6.50 million$6.10 millionViewN/AView Earnings Details
3/21/2017Q4 2016($0.28)($0.44)$5.50 million$5.79 millionViewN/AView Earnings Details
11/14/2016Q316($0.24)($0.29)$2.70 million$4.90 millionViewN/AView Earnings Details
8/15/2016Q216($0.35)$4.53 million$4.90 millionViewListenView Earnings Details
5/12/2016Q116($0.27)($0.43)$3.24 million$4.40 millionViewListenView Earnings Details
3/23/2016Q415($0.26)($0.53)$3.52 million$3.50 millionViewListenView Earnings Details
8/12/2015Q215($0.33)($0.39)$2.13 million$2.00 millionViewListenView Earnings Details
5/13/2015Q115($0.25)($0.33)$1.55 million$16.00 millionViewN/AView Earnings Details
3/12/2015Q414($0.25)($0.30)$0.68 million$0.55 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Imprimis Pharmaceuticals (NASDAQ:IMMY)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Imprimis Pharmaceuticals (NASDAQ:IMMY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Imprimis Pharmaceuticals (NASDAQ:IMMY)
Insider Ownership Percentage: 12.55%
Institutional Ownership Percentage: 17.82%
Insider Trades by Quarter for Imprimis Pharmaceuticals (NASDAQ:IMMY)
Institutional Ownership by Quarter for Imprimis Pharmaceuticals (NASDAQ:IMMY)
Insider Trades by Quarter for Imprimis Pharmaceuticals (NASDAQ:IMMY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/17/2017Robert J KammerDirectorSell10,000$3.05$30,500.00View SEC Filing  
12/19/2016Andrew R BollCFOBuy39,000$1.79$69,810.00View SEC Filing  
12/19/2016Mark L BaumCEOBuy156,000$1.79$279,240.00View SEC Filing  
12/19/2016Richard L Md LindstromDirectorBuy100,000$1.79$179,000.00View SEC Filing  
3/11/2016Opaleye Management Inc.Major ShareholderBuy45,000$3.65$164,250.00View SEC Filing  
6/30/2015Opaleye Management Inc.Major ShareholderBuy35,000$7.90$276,500.00View SEC Filing  
5/19/2015Donald Paul MiloniMajor ShareholderSell410,000$8.00$3,280,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Imprimis Pharmaceuticals (NASDAQ:IMMY)
Latest Headlines for Imprimis Pharmaceuticals (NASDAQ:IMMY)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to Imprimis Pharmaceuticals, Inc. : September 22, 2017
finance.yahoo.com - September 22 at 1:57 PM
finance.yahoo.com logoImprimis Pharmaceuticals, Inc. :IMMY-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017
finance.yahoo.com - September 20 at 4:15 PM
seekingalpha.com logoAllergan: Is Imprimis Spat Another Ruse To Crush Restasis Competitor?
seekingalpha.com - September 20 at 5:58 AM
finance.yahoo.com logoFDA Curcumin Investigation Supports Imprimis Statement
finance.yahoo.com - September 15 at 12:55 AM
americanbankingnews.com logoImprimis Pharmaceuticals (IMMY) and MyoKardia (MYOK) Financial Survey
www.americanbankingnews.com - September 12 at 11:00 AM
finance.yahoo.com logoImprimis Releases Statement Regarding Allergan Lawsuit
finance.yahoo.com - September 11 at 8:36 PM
americanbankingnews.com logoImprimis Pharmaceuticals, Inc. (IMMY) Announces Quarterly Earnings Results
www.americanbankingnews.com - August 11 at 7:54 PM
bizjournals.com logoImprimis Pharmaceuticals Announces Second Quarter 2017 Financial Results
www.bizjournals.com - August 11 at 3:53 AM
finance.yahoo.com logoInvestor Network Invites You to the Imprimis Pharmaceuticals Second Quarter 2017 Earnings Conference Call and Webcast Live on Thursday, August 10, 2017
finance.yahoo.com - August 9 at 8:08 PM
streetinsider.com logoImprimis Pharma (IMMY) Issues Statement on Curcumin Emulsion FDA MedWatch Notice
www.streetinsider.com - August 8 at 12:23 AM
finance.yahoo.com logoImprimis Statement Regarding Curcumin Emulsion FDA MedWatch Notice
finance.yahoo.com - August 7 at 7:21 PM
finance.yahoo.com logoFDA Links Naturopathic Turmeric Death To Contaminated Product
finance.yahoo.com - August 5 at 6:40 PM
finance.yahoo.com logoImprimis Pharmaceuticals to Host its Second Quarter 2017 Financial Report Conference Call and Webcast on August 10, 2017 at 4:15 p.m. EDT
finance.yahoo.com - July 31 at 7:14 PM
finance.yahoo.com logoImprimis Pharmaceuticals Patent-Pending Dropless and LessDrops Formulations Exceed One Million Patient Eyes Milestone
finance.yahoo.com - July 27 at 10:32 PM
finance.yahoo.com logoImprimis Pharmaceuticals Announces $16 Million Debt Facility with SWK Holdings
finance.yahoo.com - July 20 at 11:37 PM
americanbankingnews.com logoImprimis Pharmaceuticals, Inc. (IMMY) Director Sells $30,500.00 in Stock
www.americanbankingnews.com - July 19 at 8:22 PM
finance.yahoo.com logoImprimis Pharmaceuticals Sells Pennsylvania Facility and Sinus Assets
finance.yahoo.com - June 30 at 12:10 AM
finance.yahoo.com logoEton Pharmaceuticals Names Sean Brynjelsen Chief Executive Officer and Director
finance.yahoo.com - June 23 at 6:11 PM
benzinga.com logoImprimis Spins Off Eton Pharmaceuticals To Challenge Pricey Pipelines Of Mallinckrodt, Endo
www.benzinga.com - June 20 at 11:52 PM
finance.yahoo.com logoEton Pharmaceuticals Announces $20 Million Series A Financing
finance.yahoo.com - June 20 at 6:48 PM
finance.yahoo.com logoETFs with exposure to Imprimis Pharmaceuticals, Inc. : June 19, 2017
finance.yahoo.com - June 19 at 4:54 PM
finance.yahoo.com logoETFs with exposure to Imprimis Pharmaceuticals, Inc. : June 8, 2017
finance.yahoo.com - June 8 at 6:51 PM
finance.yahoo.com logoImprimis Pharmaceuticals, Inc. :IMMY-US: Earnings Analysis: Q1, 2017 By the Numbers : June 6, 2017
finance.yahoo.com - June 6 at 11:20 AM
americanbankingnews.com logoImprimis Pharmaceuticals Inc (IMMY) Upgraded at ValuEngine
www.americanbankingnews.com - June 4 at 11:14 AM
americanbankingnews.com logoImprimis Pharmaceuticals Inc (IMMY) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 28 at 7:02 PM
americanbankingnews.com logoImprimis Pharmaceuticals Inc (IMMY) Downgraded by ValuEngine to Strong Sell
www.americanbankingnews.com - May 16 at 3:58 PM
americanbankingnews.com logoImprimis Pharmaceuticals Inc (IMMY) Posts Quarterly Earnings Results, Misses Expectations By $0.07 EPS
www.americanbankingnews.com - May 11 at 7:36 PM
finance.yahoo.com logoImprimis Pharmaceuticals Announces First Quarter 2017 Financial Results
finance.yahoo.com - May 10 at 6:22 PM
finance.yahoo.com logoImprimis reports 1Q loss
finance.yahoo.com - May 10 at 6:22 PM
finance.yahoo.com logoInvestor Network: Imprimis Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 10 at 1:20 PM
finance.yahoo.com logoInvestor Network Invites You to the Imprimis Pharmaceuticals First Quarter 2017 Earnings Conference Call and Webcast Live on Wednesday, May 10, 2017
finance.yahoo.com - May 9 at 5:41 PM
finance.yahoo.com logoImprimis Pharmaceuticals to Launch its Simple Drops™ Combination Glaucoma Drops at Leading Cataract & Refractive Surgery Medical Meeting
finance.yahoo.com - May 4 at 6:03 PM
americanbankingnews.com logoImprimis Pharmaceuticals (IMMY) Receives Daily News Sentiment Rating of 0.31
www.americanbankingnews.com - May 2 at 10:30 PM
finance.yahoo.com logoImprimis Pharmaceuticals and SightLife Surgical Sign Agreement for National Launch of Serum Tears™
finance.yahoo.com - May 2 at 10:26 AM
finance.yahoo.com logoImprimis Pharmaceuticals to Host its First Quarter 2017 Financial Report Conference Call and Webcast …
finance.yahoo.com - May 1 at 1:20 PM
finance.yahoo.com logoImprimis Pharmaceuticals to Host its First Quarter 2017 Financial Report Conference Call and Webcast on May 10, 2017 at 4:15 p.m. EDT
finance.yahoo.com - May 1 at 1:20 PM
americanbankingnews.com logoImprimis Pharmaceuticals (IMMY) Receives Coverage Optimism Rating of 0.35
www.americanbankingnews.com - April 28 at 6:24 PM
americanbankingnews.com logoImprimis Pharmaceuticals (IMMY) Earning Favorable News Coverage, AlphaOne Reports
www.americanbankingnews.com - April 21 at 10:36 PM
finance.yahoo.com logoCan The Uptrend Continue for Imprimis Pharmaceuticals (IMMY)?
finance.yahoo.com - April 21 at 10:43 AM
americanbankingnews.com logoImprimis Pharmaceuticals (IMMY) Earns Daily News Impact Score of 0.16
www.americanbankingnews.com - April 18 at 8:50 PM
finance.yahoo.com logoImprimis Pharmaceuticals and Precision Lens Sign Agreement to Expand Imprimis' Ophthalmic Portfolio Market Opportunity in the U.S. Midwest
finance.yahoo.com - April 18 at 11:05 AM
americanbankingnews.com logoImprimis Pharmaceuticals (IMMY) Getting Somewhat Positive News Coverage, Study Finds
www.americanbankingnews.com - April 15 at 11:45 AM
americanbankingnews.com logoImprimis Pharmaceuticals Inc (IMMY) Sees Significant Increase in Short Interest
www.americanbankingnews.com - April 11 at 7:12 AM
finance.yahoo.com logoETFs with exposure to Imprimis Pharmaceuticals, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 5:46 PM
streetinsider.com logoImprimis Pharma (IMMY) Buys Exclusive License to Patented Ophthalmic Formulation for Dry Eye Disease
www.streetinsider.com - April 7 at 10:25 AM
finance.yahoo.com logoImprimis Pharmaceuticals Acquires Exclusive License to Patented Ophthalmic Formulation for Dry Eye Disease
finance.yahoo.com - April 7 at 10:25 AM
americanbankingnews.com logoAnalysts Expect Imprimis Pharmaceuticals Inc (IMMY) to Post ($0.19) EPS
www.americanbankingnews.com - April 4 at 12:01 AM
finance.yahoo.com logoCan The Uptrend Continue for Teck Resources (IMMY)?
finance.yahoo.com - March 31 at 5:56 PM
finance.yahoo.com logoImprimis Pharmaceuticals (IMMY) Jumps: Stock Rises 10%
finance.yahoo.com - March 27 at 10:59 AM
finance.yahoo.com logoIMPRIMIS PHARMACEUTICALS, INC. Financials
finance.yahoo.com - March 25 at 5:38 PM

Social

Chart

Imprimis Pharmaceuticals (IMMY) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by MarketBeat.com Staff